Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2811924 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2ATDP1BCHE | |
| SCHEMBL18025024 | 0.84 | CHRM2 (0.46) | SMN1; SMN2MEN1KMT2ACHRM2 | |
| SCHEMBL26871641 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2ATDP1BCHE | |
| SCHEMBL18025395 | 0.84 | LMNA (0.43) | SMN1; SMN2TDP1BCHEALDH1A1ANPEP | |
| SCHEMBL11720276 | 0.82 | BCHE (0.54) | SMN1; SMN2MEN1KMT2ABCHEALDH1A1 | |
| SCHEMBL3193069 | 0.82 | MEN1 (0.53) | SMN1; SMN2MEN1KMT2ATDP1MAOA | |
| SCHEMBL1285550 | 0.82 | SIGMAR1 (0.50) | MEN1KMT2AANPEPATMMAPT | |
| SCHEMBL1285846 | 0.82 | GAA (0.43) | SMN1; SMN2KMT2ATDP1ALDH1A1TP53 | |
| SCHEMBL3168512 | 0.81 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2ATDP1BCHE | |
| SCHEMBL24400255 | 0.81 | ANPEP (0.52) | SMN1; SMN2ALDH1A1ANPEPCHRM2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4225760-A1 | NOVEL BICYCLIC COMPOUNDS | PRISM BioLab Co., Ltd. (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| CN-116348119-A | Novel bicyclic compounds | 株式会社棱镜生物实验室 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023090366-A1 | ANTICANCER AGENT AND CARDIAC-FUNCTION-IMPROVING AGENT | 株式会社 PRISM BioLab | 2023-05-25 | — | — | WO | disclosed |
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2005-04-07 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| EP-1456186-A1 | NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A SB 2 /SB PHOSPHOLIPASE OF GROUP II | Yang Ji Chemical Company Ltd. (KR) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004035587-A1 | REVERSE-TURN MIMETICS AND COMPOSITION AND METHODS RELATING THERETO | MYRIAD GENETICS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004024078-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003104257-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003048139-A1 | NOVEL INHIBITOR COMPOUNDS SPECIFIC OF SECRETED NON-PANCREATIC HUMAN A2 PHOSPHOLIPASE OF GROUP II | YANG JI CHEMICAL COMPANY LTD. (KR) | 2003-06-12 | — | — | WO | disclosed |
| US-4431815-A | CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS | BURROUGHS WELLCOME CO. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | NOTCH1, NOTCH2, HES1 | SMN1; SMN2 3463/4885MEN1 314/4885KMT2A 2051/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | SMN1; SMN2 3678/4885MEN1 4394/4885KMT2A 3816/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | SMN1; SMN2 1888/4885MEN1 138/4885KMT2A 850/4885 |
| US-20040214838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | SMN1; SMN2 3678/4885MEN1 4394/4885KMT2A 3816/4885 |
| US-20050075345-A1 | Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II | AMY2A, PNLIP, IAPP | SMN1; SMN2 2465/4885MEN1 1731/4885KMT2A 3741/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | SMN1; SMN2 1888/4885MEN1 138/4885KMT2A 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.